Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Cocrystal Pharma Inc

Company price
0.9801 USD -0.01 ( 1.00%)
Last update at 2026-11-13T21:00:00Z
VOLUME
10303
Market Cap
19.71M

Momentum Score

…

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.98
Low
1.03
High
52 Week Price Range
0.86
Low
2.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cocrystal Pharma Inc is a clinical-stage biotechnology company developing antiviral therapeutics through structure-based drug discovery to create oral small-molecule antivirals for acute and chronic viral infections. Long-term growth may be driven by clinical trial progress, successful regulatory approvals or licensing partnerships, and broader demand for effective viral treatments, which appears positioned to reward programs that demonstrate safety and efficacy.
Material risks include high clinical and regulatory uncertainty, limited operating history and cash runway that may require dilutive financing, and strong competition from larger antiviral developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.99
Dividend Yield
-
Revenue TTM
0.51M
Revenue Per Share
0.01
Gross Profit TTM
-5.05M
Debt / Equity
0.24
ROE
-111.40%
Net Debt
-5.52M
ROCE
-120.22%
Diluted EPS TTM
-0.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.83M -17.50M -17.98M -38.84M -14.19M
Net income -8.83M -17.50M -17.98M -38.84M -14.19M
Selling general administrative 3.96M 5.34M 5.99M 5.75M 5.43M
Selling and marketing expenses - - 7.37M - -
Gross profit -0.38M -12.54M -15.17M -0.24M -0.24M
Reconciled depreciation 0.38M 0.45M 0.41M 0.39M 0.38M
Ebit -9.02M -17.88M -21.16M -38.83M -14.22M
Ebitda -8.64M -17.75M -20.97M -17.75M -14.03M
Depreciation and amortization 0.38M 0.13M 0.19M 21.08M 0.19M
Operating income -9.02M -17.88M -18.56M -38.83M -14.22M
Other operating expenses 9.02M 17.88M 18.56M 18.14M 14.22M
Interest expense - - - 0.00M 0.00M
Net interest income 0.13M 0.54M 0.46M -0.00M -0.00M
Income tax expense - -17.50M -0.00M 0.01M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 5.43M
Total operating expenses 8.64M 5.34M 3.39M 18.14M 14.22M
Cost of revenue 0.38M 12.54M 15.17M 0.24M 0.24M
Total other income expense net 0.19M 0.37M 0.57M -0.01M 0.04M
Net income from continuing ops -8.83M -17.50M -18.02M -38.84M -14.19M
Net income applicable to common shares - - - -38.84M -14.19M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.71M 13.46M 31.26M 40.84M 79.39M
Other current assets 0.40M 0.51M 1.77M 2.24M 0.57M
Total liab 3.38M 3.93M 4.88M 1.27M 1.84M
Total stockholder equity 6.33M 9.52M 26.38M 39.57M 77.55M
Other current liab 0.99M 0.23M 1.80M 0.36M 0.01M
Common stock 0.01M 0.01M 0.01M 0.01M 0.10M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.10M
Retained earnings -342.25M -333.42M -315.91M -297.93M -259.09M
Good will - - - 0.00M 19.09M
Other assets - - 0.00M 0.05M 0.05M
Cash 7.03M 9.86M 26.43M 37.14M 58.70M
Total current liabilities 2.21M 2.43M 3.26M 1.22M 1.54M
Current deferred revenue - - - - 0.72M
Net debt -5.52M -8.05M -24.57M -36.85M -58.17M
Short term debt 0.33M 0.60M 0.24M 0.24M 0.24M
Short long term debt total 1.50M 1.81M 1.85M 0.30M 0.53M
Other stockholder equity 348.57M 342.93M 342.29M 337.49M 336.54M
Property plant equipment - - - 0.62M 0.93M
Total current assets 8.13M 11.58M 29.09M 40.18M 59.32M
Net tangible assets - - - 39.57M 58.46M
Net receivables 0.71M 1.22M 0.89M 0.72M 0.00M
Inventory - - - 0.07M -
Accounts payable 0.89M 1.54M 1.22M 0.61M 0.58M
Non currrent assets other 0.10M 0.03M 0.05M 0.05M 0.05M
Non current assets total 1.58M 1.88M 2.17M 0.66M 20.07M
Capital lease obligations 1.50M 1.81M 1.85M 0.30M 0.53M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01M -0.07M -0.07M -0.05M
Change to liabilities - - - -1.04M 0.22M
Total cashflows from investing activities -0.01M -0.01M -0.12M -0.07M -0.05M
Net borrowings - 0.00M -0.01M -0.03M -0.04M
Total cash from financing activities 5.37M 0.00M 3.99M -0.03M 38.47M
Change to operating activities - - - -1.68M -0.17M
Net income -8.83M -17.50M -17.98M -38.84M -14.19M
Change in cash -2.83M -16.49M -10.79M -21.54M 25.70M
Begin period cash flow 9.94M 26.43M 37.22M 58.76M 33.06M
End period cash flow 7.10M 9.94M 26.43M 37.22M 58.76M
Total cash from operating activities -8.19M -16.48M -14.67M -21.43M -12.72M
Issuance of capital stock 5.37M 0.00M 4.00M 0.00M 38.51M
Depreciation 0.07M 0.13M -1.39M 0.39M 0.19M
Change to account receivables 0.51M -0.33M -0.17M 0.00M 0.56M
Other cashflows from financing activities 5.37M - 0.00M -0.07M -0.05M
Change to netincome - - - 19.73M 0.48M
Capital expenditures 0.01M 0.01M 0.12M 0.07M 0.05M
Change in working capital 0.29M 0.14M 2.34M -2.71M 0.80M
Stock based compensation 0.27M 0.64M 0.80M 0.85M 0.72M
Other non cash items 0.00M 0.11M 1.56M 18.87M -0.20M
Free cash flow -8.20M -16.49M -14.78M -21.51M -12.77M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
COCP
Cocrystal Pharma Inc
-0.01
1.00%
0.98 - - 92.45 3.15 0.71 0.66
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.

19805 North Creek Parkway, Bothell, WA, United States, 98011

877 262 7123

10

Name Title Year Born
Dr. Roger D. Kornberg Ph.D. Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board 1947
Dr. Sam Lee Ph.D. Co-Founder, Interim Co-CEO & Pres 1960
Mr. James J. Martin CPA, CPA, M.B.A., MBA Interim Co-CEO, CFO & Corp. Sec. 1967
Dr. Roger D. Kornberg Ph.D. Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board 1947
Dr. Sam Lee Ph.D. Co-Founder, Co-CEO & President 1960
Mr. James J. Martin CPA, M.B.A. Co-CEO, CFO & Corporate Secretary 1967
Dr. Roger D. Kornberg Ph.D. Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board 1947
Prof. Roger D. Kornberg Ph.D. Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board 1947

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…